Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells

The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line

(2015) Kazumi Hagiwara et al.   APOPTOSIS

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

(2015) R. Chen et al.   HAEMATOLOGICA

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

(2015) R. Chen et al.   HAEMATOLOGICA

SnapShot: Diffuse Large B Cell Lymphoma

(2014) Laura Pasqualucci et al.   CANCER CELL

Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma

(2014) N. Kaneko et al.   CLINICAL CANCER RESEARCH

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma

(2013) Jeffrey L. Vacirca et al.   ANNALS OF HEMATOLOGY

Mechanisms of epigenetic deregulation in lymphoid neoplasms

(2013) Y. Jiang et al.   BLOOD

The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways

(2013) Juraj Bodo et al.   BRITISH JOURNAL OF HAEMATOLOGY

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma

(2013) Ana A Tula-Sanchez et al.   CANCER BIOLOGY & THERAPY

The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms

(2013) Ying Cai et al.   Cancer Cell International

Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2013) Ken Ohmachi et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

(2013) Paul G. Richardson et al.   LEUKEMIA RESEARCH

The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein Activity

(2013) Ryan C. Thompson et al.   PLoS One

Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma

(2013) N Hiraoka et al.   Blood Cancer Journal

Treatment strategies for aggressive lymphomas: what works?

(2013) W. H. Wilson   Hematology-American Society of Hematology Education Program

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

(2012) Z. Y. Xu-Monette et al.   BLOOD

Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies

(2012) Anna Korycka-Wołowiec et al.   Expert Opinion on Drug Metabolism & Toxicology

Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy

(2012) Eva Walter et al.   LEUKEMIA & LYMPHOMA

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8

(2012) W Yan et al.   ONCOGENE

Dose Dependent Effects on Cell Cycle Checkpoints and DNA Repair by Bendamustine

(2012) Neil Beeharry et al.   PLoS One

Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

(2011) Mark Kirschbaum et al.   JOURNAL OF CLINICAL ONCOLOGY

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

(2011) Ryan D. Morin et al.   NATURE

Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo

(2011) Valentina Zuco et al.   PLoS One

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

(2010) G. Dasmahapatra et al.   BLOOD

γH2AX: a sensitive molecular marker of DNA damage and repair

(2010) L-J Mah et al.   LEUKEMIA

Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8

(2009) Michael R. Garbati et al.   CANCER LETTERS

Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53

(2009) Blanca Sanchez-Gonzalez et al.   LEUKEMIA & LYMPHOMA

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

(2008) M. Crump et al.   ANNALS OF ONCOLOGY

Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling

(2008) G. Roue et al.   CLINICAL CANCER RESEARCH

Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

(2008) L. M. Leoni et al.   CLINICAL CANCER RESEARCH

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

(2008) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY